← Back to Search

Immunoglobulin

Open Label study for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (Panzyga-CIDP Trial)

Phase 3
Waitlist Available
Research Sponsored by Vera Bril
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Summary

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral neuropathy with suspected autoimmune cause. The current first-line treatment is IVIG (immune globulin), which is infused in a set regimen that requires 4-5 hours in a hospital day unit, taking up resources such as nursing time and hospital space. Chronic treatment is required in most cases.

Eligible Conditions
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Occurrence of all adverse events with focus on adverse drug reactions (ADRs)
Secondary study objectives
grip strength
health utilities
proportion of patients successfully achieving higher infusion rates
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open Label studyExperimental Treatment1 Intervention
open label study using Panzyga immune globulin 10% intravenous solution with no placebo.

Find a Location

Who is running the clinical trial?

Vera BrilLead Sponsor
~4 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top